

INVESTOR DAY 2023

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Included in Investor Day Materials

CVS Health Corporation (the “Company”) uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance. These non-GAAP financial measures are provided as supplemental information to the financial measures the Company discloses that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measurements reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (EPS) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. Effective January 1, 2023, the Company’s non-GAAP financial measures also exclude the impact of net realized capital gains or losses, described in further detail below. Additionally, effective January 1, 2023, the Company realigned the composition of its segments and adopted a new accounting standard related to the accounting for long-duration insurance contracts. Refer to our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 for further information. Prior period financial information throughout this document has been revised to conform with the current period presentation.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of the Company. The information within this document is forward-looking, including information related to full year 2023 and 2024 financial guidance. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may also differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our most recent Quarterly Report on Form 10-Q and our recent Current Reports on Form 8-K.

You are cautioned not to place undue reliance on the Company’s forward-looking statements. The Company’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. The Company does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

ADJUSTED EARNINGS PER SHARE

GAAP diluted EPS and Adjusted EPS, respectively, are calculated by dividing net income attributable to CVS Health and adjusted income attributable to CVS Health by the Company’s weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, losses on assets held for sale, opioid litigation charges, gains/losses on divestitures, the corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and certain discrete tax items, as well as any other items specifically identified herein.

INVESTOR DAY 2023

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Included in Investor Day Materials

The following are reconciliations of projected GAAP diluted EPS to projected Adjusted EPS:

	Year Ending December 31,				
	2024E	2023E			2022
	At Least	Low	Mid	High	Actual
<i>In millions, except per share amounts</i>					
Net income attributable to CVS Health (GAAP measure)	\$ 7.26	\$ 6.37	\$ 6.49	\$ 6.61	\$ 3.26
<i>Non-GAAP adjustments:</i>					
Amortization of intangible assets	1.58	1.48	1.47	1.47	1.35
Net realized capital (gains) losses	—	0.27	0.27	0.27	0.24
Acquisition-related transaction and integration costs ⁽¹⁾	0.18	0.34	0.33	0.32	—
Restructuring charges ⁽²⁾	—	0.39	0.39	0.39	—
Office real estate optimization charges ⁽³⁾	—	0.06	0.06	0.05	0.09
Loss on assets held for sale ⁽⁴⁾	—	0.27	0.27	0.27	1.91
Opioid litigation charges ⁽⁵⁾	—	—	—	—	4.39
Gain on divestiture of subsidiaries ⁽⁶⁾	—	—	—	—	(0.36)
Tax impact of non-GAAP adjustments ⁽⁷⁾	(0.52)	(0.68)	(0.68)	(0.68)	(1.85)
Adjusted income attributable to CVS Health	\$ 8.50	\$ 8.50	\$ 8.60	\$ 8.70	\$ 9.03
Weighted average diluted shares outstanding	1,263	1,291	1,291	1,291	1,323

- (1) During 2024 and 2023, the acquisition-related transaction and integration costs relate to the acquisitions of Signify Health, Inc. ("Signify Health") and Oak Street Health, Inc. ("Oak Street Health").
- (2) During 2023, the restructuring charges are primarily comprised of severance and employee-related costs, asset impairment charges and a stock-based compensation charge. During the second quarter of 2023, the Company developed an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with the development of this plan and the recently completed acquisitions of Signify Health and Oak Street Health, the Company also conducted a strategic review of its various transformation initiatives and determined that it would terminate certain initiatives.
- (3) During 2023 and 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company's new flexible work arrangement.
- (4) During 2023 and 2022, the loss on assets held for sale relates to the Company's long-term care ("LTC") reporting unit within the Pharmacy & Consumer Wellness segment. During 2022, the Company determined that its LTC business was no longer a strategic asset and committed to a plan to sell it, at which time the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and, accordingly, the Company recorded a loss on assets held for sale during the year ended December 31, 2022. During the first quarter of 2023, a loss on assets held for sale was recorded to write down the carrying value of the LTC business to the Company's best estimate of the ultimate selling price which reflects its estimated fair value less costs to sell. As of September 30, 2023, the Company determined the LTC business no longer met the criteria for held-for-sale accounting and accordingly the net assets associated with the LTC business were reclassified to held and used at their respective fair values. During 2022, the loss on assets held for sale also relates to the Company's international health care business domiciled in Thailand ("Thailand business"), which was included in the Commercial Business reporting unit in the Health Care Benefits segment. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.
- (5) During 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities.
- (6) During 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift LLC ("bswift"), which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex Holdings, Inc. ("PayFlex"), which the Company sold in June 2022.
- (7) Represents the corresponding tax benefit or expense related to the items excluded from Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision. During 2022, the Company's adjusted income tax provision also excludes the impact of certain discrete tax items concluded in the first quarter of 2022.

INVESTOR DAY 2023

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Included in Investor Day Materials

ADJUSTED OPERATING INCOME

The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, losses on assets held for sale, opioid litigation charges and gains/losses on divestitures. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company's ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. The following are reconciliations of projected operating income to projected adjusted operating income:

CONSOLIDATED

<i>In millions</i>	Year Ending December 31,			
	2024E	2023E		2022
	At Least	Low	High	Actual
Operating income (GAAP measure)	\$ 15,009	\$ 13,587	\$ 13,992	\$ 7,954
Amortization of intangible assets	2,000	1,915	1,895	1,785
Net realized capital (gains) losses	—	345	345	320
Acquisition-related transaction and integration costs ⁽¹⁾	230	440	420	—
Restructuring charges ⁽²⁾	—	507	507	—
Office real estate optimization charges ⁽³⁾	—	70	60	117
Loss on assets held for sale ⁽⁴⁾	—	349	349	2,533
Opioid litigation charges ⁽⁵⁾	—	—	—	5,803
Gain on divestiture of subsidiaries ⁽⁶⁾	—	—	—	(475)
Adjusted operating income	\$ 17,239	\$ 17,213	\$ 17,568	\$ 18,037

- (1) During 2024 and 2023, the acquisition-related transaction and integration costs relate to the acquisitions of Signify Health and Oak Street Health.
- (2) During 2023, the restructuring charges are primarily comprised of severance and employee-related costs, asset impairment charges and a stock-based compensation charge. During the second quarter of 2023, the Company developed an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with the development of this plan and the recently completed acquisitions of Signify Health and Oak Street Health, the Company also conducted a strategic review of its various transformation initiatives and determined that it would terminate certain initiatives.
- (3) During 2023 and 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company's new flexible work arrangement.
- (4) During 2023 and 2022, the loss on assets held for sale relates to the Company's LTC reporting unit within the Pharmacy & Consumer Wellness segment. During 2022, the Company determined that its LTC business was no longer a strategic asset and committed to a plan to sell it, at which time the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and, accordingly, the Company recorded a loss on assets held for sale during the year ended December 31, 2022. During the first quarter of 2023, a loss on assets held for sale was recorded to write down the carrying value of the LTC business to the Company's best estimate of the ultimate selling price which reflects its estimated fair value less costs to sell. As of September 30, 2023, the Company determined the LTC business no longer met the criteria for held-for-sale accounting and accordingly the net assets associated with the LTC business were reclassified to held and used at their respective fair values. During 2022, the loss on assets held for sale also relates to the Company's Thailand business, which was included in the Commercial Business reporting unit in the Health Care Benefits segment. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.
- (5) During 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities.
- (6) During 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022.

INVESTOR DAY 2023

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures Included in Investor Day Materials

HEALTH CARE BENEFITS SEGMENT

<i>In millions</i>	Year Ending December 31,				
	2024E		2023E		2022
	At Least	Low	High	Actual	
Operating income (GAAP measure)	\$ 4,621	\$ 4,096	\$ 4,236	\$ 5,270	
Amortization of intangible assets	1,149	1,178	1,178	1,180	
Net realized capital (gains) losses	—	296	296	225	
Office real estate optimization charges ⁽¹⁾	—	60	50	97	
Loss on assets held for sale ⁽²⁾	—	—	—	41	
Gain on divestiture of subsidiaries ⁽³⁾	—	—	—	(475)	
Adjusted operating income	\$ 5,770	\$ 5,630	\$ 5,760	\$ 6,338	

- (1) During 2023 and 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company's new flexible work arrangement.
- (2) During 2022, the loss on assets held for sale relates to the Company's Thailand business, which was included in the Commercial Business reporting unit. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material.
- (3) During 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022.

HEALTH SERVICES SEGMENT

<i>In millions</i>	Year Ending December 31,				
	2024E		2023E		2022
	At Least	Low	High	Actual	
Operating income (GAAP measure)	\$ 6,887	\$ 6,702	\$ 6,847	\$ 6,612	
Amortization of intangible assets	602	475	455	167	
Office real estate optimization charges ⁽¹⁾	—	6	6	2	
Adjusted operating income	\$ 7,489	\$ 7,183	\$ 7,308	\$ 6,781	

- (1) During 2023 and 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company's new flexible work arrangement.

PHARMACY & CONSUMER WELLNESS SEGMENT

<i>In millions</i>	Year Ending December 31,				
	2024E		2023E		2022
	At Least	Low	High	Actual	
Operating income (GAAP measure)	\$ 5,262	\$ 5,146	\$ 5,246	\$ 3,560	
Amortization of intangible assets	246	259	259	435	
Net realized capital (gains) losses	—	4	4	44	
Loss on assets held for sale ⁽¹⁾	—	349	349	2,492	
Adjusted operating income	\$ 5,508	\$ 5,758	\$ 5,858	\$ 6,531	

- (1) During 2023 and 2022, the loss on assets held for sale relates to the Company's LTC reporting unit within the Pharmacy & Consumer Wellness segment. During 2022, the Company determined that its LTC business was no longer a strategic asset and committed to a plan to sell it, at which time the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and, accordingly, the Company recorded a loss on assets held for sale during the year ended December 31, 2022. During the first quarter of 2023, a loss on assets held for sale was recorded to write down the carrying value of the LTC business to the Company's best estimate of the ultimate selling price which reflects its estimated fair value less costs to sell. As of September 30, 2023, the Company determined the LTC business no longer met the criteria for held-for-sale accounting and accordingly the net assets associated with the LTC business were reclassified to held and used at their respective fair values.

INVESTOR DAY 2023
**Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable
GAAP Financial Measures Included in Investor Day Materials**

ADJUSTED EFFECTIVE INCOME TAX RATE

The following are reconciliations of the projected effective income tax rate to the projected adjusted effective income tax rate:

CONSOLIDATED

	Year Ending December 31,		
	2024	2023	2022
	Estimated	Estimated	Actual
Effective income tax rate (GAAP measure)	24.6 %	25.1 %	25.9 %
Impact of non-GAAP adjustments ⁽¹⁾	0.8	(0.2)	(1.0)
Adjusted effective income tax rate	25.4 %	24.9 %	24.9 %

- (1) Removes the corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health for the year ended December 31, 2022 and projected adjusted income attributable to CVS Health for the years ending December 31, 2023 and 2024 that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance, such as amortization of intangible assets, net realized capital gains or losses, acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, losses on assets held for sale, opioid litigation charges and gains/losses on divestitures. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision. During 2022, the Company's adjusted effective income tax rate also excludes the impact of certain discrete tax items concluded in the first quarter of 2022.

FREE CASH FLOW

The Company defines free cash flow as net cash provided by operating activities less capital expenditures and risk-based capital. The following are reconciliations of projected cash flows from operations to projected free cash flow:

CONSOLIDATED

	2024-2026E 3 Year Average At Least
<i>In billions</i>	
Cash flow from operations (GAAP measure)	\$ 12.5
Less: Capital expenditures	(3.0)
Less: Risk-based capital	(2.5)
Free cash flow	\$ 7.0

INVESTOR DAY 2023
**Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable
GAAP Financial Measures Included in Investor Day Materials**

LEVERAGE RATIO CALCULATION

The Company defines Leverage Ratio as Adjusted Net Debt divided by adjusted earnings before interest, tax, depreciation and amortization (Adjusted EBITDA). Adjusted Net Debt is defined as short-term debt and total long-term debt, including the current portion of long-term debt (GAAP measure), plus the current and long-term portion of operating lease liabilities (GAAP measure) reported on the Company's unaudited condensed consolidated balance sheets, plus, effective June 30, 2023, the present value of payments related to agreements to resolve substantially all opioid claims against the Company (the "opioid litigation liabilities"), less cash and cash equivalents held by the parent company or nonrestricted subsidiaries. Upon discussions with the Company's rating agencies during the second quarter of 2023, effective June 30, 2023, the Company began including the present value of the opioid litigation liabilities in its calculation of Adjusted Net Debt-to-EBITDA in order to remain consistent with the methodologies of those rating agencies. Adjusted EBITDA is defined as the trailing twelve months of (i) net income (GAAP measure) plus income taxes, interest, depreciation and amortization plus (ii) operating lease costs, and (iii) other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, losses on assets held for sale and any other items specifically identified herein.

For reconciliations of total debt to Adjusted Net Debt and net income to Adjusted EBITDA as well as a calculation of Adjusted Net Debt to Adjusted EBITDA as of September 30, 2023 refer to the third quarter 2023 reconciliations on the Investor Relations portion of our website.